Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Assessing Targeted PET Imaging for Advanced Rectal Cancer. By Jordyn Sava. October 3rd 2024. In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.
Targeted Therapies in Oncology - Targeted Oncology
December 1, 2022. Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with its meeting coverage, columns, FDA news, and more. Click Here to Subscribe.
Schneider Examines Anal Carcinoma Prognosis - Targeted Oncology
2022年5月30日 · Currently, anal carcinoma is rare and has a low mortality rate. However, the lower incidence of mortality comes after years of increasing mortality in the space, according to Schneider. The incidence increased by roughly 2.7% and the mortality rate increasing by roughly 3.1% year over year. A preventative strategy for anal carcinoma is the ...
Defining Unresectable and Advanced HCC - Targeted Oncology
2021年7月20日 · After the approval of sorafenib, we had numerous negative studies, until the REFLECT study. This transcript has been edited for clarity. Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.
ADRIATIC Study Highlights Survival Gains With Durvalumab in LS …
2024年8月25日 · T he ADRIATIC study evaluated the use of durvalumab (Imfinzi) as consolidation treatment after concurrent chemoradiation in patients with LS-SCLC. Improved survival outcomes were observed with this consolidation treatment, according to data shared during a press briefing at the 2024 American Society of Clinical Oncology Annual Meeting. At a ...
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
2024年1月25日 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
Sunvozertinib Shows Activity and Tolerability in EGFR Exon 20
2022年11月18日 · Sunvozertinib (DZD9008) has demonstrated activity in patients with non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation across mutation types and prior treatments, according to data pooled from 3 phase 1/2 clinical trials. Findings from the clinical trials were presented at the International Associationfor the Study of Lung Cancer 2022 North America Conference on ...
Merck Halts 2 Phase 3 KEYNOTE Studies of Pembrolizumab in …
2024年8月30日 · Merck is halting the phase 3 KEYNOTE-867 study (NCT03924869) and KEYNOTE-630 study (NCT03833167) of pembrolizumab (Keytruda) due to futility, based on recommendations from an independent data monitoring committee. 1 KEYNOTE-867 was evaluating pembrolizumab, the anti–PD-1 therapy, in combination with stereotactic body radiotherapy (SBRT) for the treatment of stage I or II non–small cell ...
FDA’s ODAC Finds Cilta-Cel Favorable in R/R Multiple Myeloma
2024年3月15日 · Article. During an Oncologic Drugs Advisory Committee Meeting, the FDA found that ciltacabtagene autoleucel has a favorable benefit/risk profile in relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy and are refractory to lenalidomide. Ciltacabtagene autoleucel (cilta-cel; Carvykti) is a chimeric antigen ...
FDA Grants Fast Track Designation to Momelotinib for …
2019年6月6日 · Srdan Verstovesk, MD, PhD. The FDA has granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor. 1 Momelotinib is a selective inhibitor of JAK1, JAK2, and ACVR1 that has demonstrated benefit towards improving anemia in patients with myelofibrosis.